13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
88 檔
9.2%
According to the latest 13F quarterly dataset, Affinity Asset Advisors, LLC managed an equity portfolio of $2.2B at the end of Q2 2025, spanning 88 distinct U.S. exchange-listed positions.
During Q2 2025, Affinity Asset Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.88% | — | -0.81% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 6.53% | -0.92% | +239.29% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.70% | -0.68% | -17.18% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 4.45% | -2.15% | EXIT | |
| 5 | 2655787D | Blueprint Medicines CORP | Stock-Other | 4.38% | — | — | |
| 6 | NUVL | Nuvalent Inc-a | Stock-Other | 4.32% | -0.05% | -9.78% | |
| 7 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.12% | +0.33% | -39.68% | |
| 8 | ALKS | Alkermes plc | Stock-Healthcare | 3.91% | +0.79% | — | |
| 9 | EXEL | Exelixis Inc | Stock-Healthcare | 3.61% | — | +344.44% | |
| 10 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.32% | +0.01% | -23.14% | |
| 11 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.31% | -0.52% | — | |
| 12 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 3.20% | -1.61% | — | |
| 13 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.97% | -0.28% | +142.38% | |
| 14 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.96% | +0.31% | -9.35% | |
| 15 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.95% | +0.28% | +19.59% | |
| 16 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.89% | +0.29% | +102.72% | |
| 17 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.78% | -0.52% | EXIT | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 1.75% | -0.04% | -12.12% | |
| 19 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.66% | -0.14% | -30.77% | |
| 20 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.62% | -2.87% | EXIT | |
| 21 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.59% | — | — | |
| 22 | AMGN | Amgen Inc | Stock-Healthcare | 1.53% | — | -42.86% | |
| 23 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.51% | +0.29% | +19.36% | |
| 24 | RZLT | Rezolute Inc | Stock-Other | 1.34% | — | +29.41% | |
| 25 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.33% | -0.12% | — | |
| 26 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.33% | — | — | |
| 27 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.24% | +1.80% | +25.95% | |
| 28 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.10% | -0.04% | — | |
| 29 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.98% | +0.26% | +6.55% | |
| 30 | AKBA | Akebia Therapeutics Inc | Stock-Other | 0.97% | — | +30.00% | |
| 31 | OMER 9.5 06-15-29Bond | Omeros CORP | Bond | 0.97% | -0.13% | — | |
| 32 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.96% | — | -54.77% | |
| 33 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.95% | — | — | |
| 34 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.92% | +1.27% | +10.66% | |
| 35 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.91% | — | — | |
| 36 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.88% | -0.58% | EXIT | |
| 37 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.74% | -0.04% | — | |
| 38 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.71% | — | -50.00% | |
| 39 | ERAS | Erasca Inc | Stock-Other | 0.71% | -0.12% | +22.27% | |
| 40 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.68% | -0.03% | -44.98% | |
| 41 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.62% | — | — | |
| 42 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.62% | +1.99% | +166.67% | |
| 43 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.60% | -0.01% | — | |
| 44 | PCVX | Vaxcyte Inc | Stock-Other | 0.56% | — | +400.00% | |
| 45 | ✓ | Stock-Other | 0.51% | — | — | ||
| 46 | ✓ | Merus N V | Stock-Other | 0.50% | — | -78.26% | |
| 47 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.49% | -0.03% | -52.79% | |
| 48 | QURE | uniQure N.V. | Stock-Other | 0.45% | +0.53% | -41.25% | |
| 49 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.41% | +1.39% | -7.50% | |
| 50 | ✓ | Stock-Other | 0.36% | -0.02% | — |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 88 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, INSM, XENE) accounted for 9.2% of total reported equity market value during Q2 2025.
During Q2 2025, Affinity Asset Advisors, LLC's top holdings by market value included VRNA (7.9%)、INSM (6.5%)、XENE (4.7%). The largest single position, VRNA, represented 7.9% of total portfolio value.
In Q2 2025, Affinity Asset Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.